Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
The drop started when Pfizer announced its vaccine was on the way! retail shat itself and sold on mass resulting in a lot of people losing money due to stop losses being triggered etc. ****ging the Bod of and emailing the company every 5 mins is not going to affect the sp. MMs and volume will. Chill, and drink wine...
Reabold's expected work programme for 2020 is fully-funded by cash already invested into the operating businesses. The programme includes the testing of West Newton A-2, the drilling of two wells at West Newton B, the testing of IM-1 and the drilling of IM-2 in Romania, and the drilling of additional wells in California. We believe that these projects remain highly economic at current oil prices.
Page 8 show a sidetrack image from West newton B
https://reabold.com/wp-content/uploads/2017/10/Corporate-Presentation-February-2020-FINAL-05.02.20.pdf
These guys don't back losers.
https://reabold.com/investor-relations/share-information/
60 million-plus antibody test to start, them periodic testing over the coming years to check antibody levels prior to booster shots.
https://www.tuneskit.com/spotify-music-tips/napster-vs-spotify.html#:~:text=Napster%20provides%20the%20highest%20streaming%20quality%20as%20320kb%2Fs,quality%20is%20consistent%20with%20the%20current%20streaming%20bitrate.
The Board of Tiziana Life Sciences Inc has announced that it intends to demerge its StemPrintER and SPARE business into a separate company, Accustem Sciences Limited. Subject to Court approval at a Hearing to be held on 27 October 2020, Shareholders as at close of business on 30 October 2020 will receive 1 additional Accustem Sciences Limited share for every Tiziana Life Sciences plc share held.
The new Accustem Sciences Limited shares will not be trading immediately as the Company has to apply for admission to list on the London Stock Exchange. It is expected that the new shares will be admitted to trading on the London Stock Exchange on a date expected to be in the fourth quarter of 2020.
We will credit your account with a dummy line of stock representing your entitlement to Accustem Sciences Limited shares whilst we await the new shares.
You will be sent confirmation once the new shares have been credited to your Account.
The Board of Tiziana Life Sciences Inc has announced that it intends to demerge its StemPrintER and SPARE business into a separate company, Accustem Sciences Limited. Subject to Court approval at a Hearing to be held on 27 October 2020, Shareholders as at close of business on 30 October 2020 will receive 1 additional Accustem Sciences Limited share for every Tiziana Life Sciences plc share held.
The new Accustem Sciences Limited shares will not be trading immediately as the Company has to apply for admission to list on the London Stock Exchange. It is expected that the new shares will be admitted to trading on the London Stock Exchange on a date expected to be in the fourth quarter of 2020.
We will credit your account with a dummy line of stock representing your entitlement to Accustem Sciences Limited shares whilst we await the new shares.
You will be sent confirmation once the new shares have been credited to your Account.
STEMPRINTER SCIENCES LIMITED (12856894)
https://find-and-update.company-information.service.gov.uk/officers/IoU9S7f850CYDGQ2IJRI-Qn8PN4/appointments
Entering a stop-loss order with your broker will automatically generate a sell order should the stock drop to that number. A market maker can see that number and may drop down to buy your stock at the low price and then resell it for a profit.
https://twitter.com/trashhousepanda/status/1309093450437009408/photo/1
Patience young grasshopper...
https://www.rathlin-energy.co.uk/latest-update/
I agree. But, if the government needs to deploy them it will.
The British Armed Forces are a professional force with a strength of 149,080 UK Regulars and Gurkhas, 37,060 Volunteer Reserves and 7,840 "Other Personnel" as of 1 April 2020. This gives a total strength of 193,980 "UK Service Personnel".
Financial broker finnCap reckons Omega could ultimately be looking at £8m-£12m of revenue from its food intolerance testing business and £37m in revenues from Covid test sales. The group’s HIV test, VISITECT CD4, could be worth between £45m to £75m.
House broker finnCap has estimated that Omega will receive approximately £3.20 for each packaged and labelled test, with a gross margin in the region of 50 per cent. This would imply peak weekly revenues of approximately £300,000.
Apparently a scientist from Oxford said a vaccine will be 2-3 years away.
Saliva home test for COVID-19 - 99% accurate.
I had a chat today with one of the Ulster Uni students doing the survey and she mentioned that a blanket survey of the country would give the government valuable demographic data of how the virus has spread. However, more testing will be carried out. GP surgeries and A&E departments I recon will be next as standard. Gold standard...